Regencell Bioscience
3 hedge funds and large institutions have $1.89K invested in Regencell Bioscience in 2024 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0.32% less ownership
Funds ownership: 0.48% → 0.16% (-0.32%)
75% less capital invested
Capital invested by funds: $7.43K → $1.89K (-$5.54K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $1.05K | -$5.12K | -41,344 | -78% |
|
2
BlackRock
New York
| $800 | – | – | – |
|
3
Qube Research & Technologies (QRT)
London,
United Kingdom
| $44 | – | – | – |
|
RGC Hedge Fund Activity: Q2 2024 in Review
3 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q2 2024, worth a combined $1.89K — down 75% from $7.43K a quarter earlier.
Fund positioning in RGC was balanced in Q2 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $5.12K.
- 3 institutional investors held Regencell Bioscience (RGC) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $1.89K of Regencell Bioscience stock for Q2 2024, down 75% quarter-over-quarter.
- 0 funds opened new Regencell Bioscience positions in Q2 2024 and 0 closed out.
- The largest Regencell Bioscience seller in Q2 2024 was UBS Group, an estimated $5.12K sold.
Based on aggregated 13F filings for Q2 2024.